GLP-1/GIP is a dual-action metabolic therapy that works with your body’s natural hormones to improve appetite control, stabilize blood sugar, and support long-term weight loss. It enhances both satiety and metabolic efficiency for stronger, more sustained results.

Most patients begin noticing appetite and craving changes within the first 1–2 weeks. Visible weight loss typically follows within the first month, with more significant results appearing around weeks 6–8 depending on dosage and consistency.

GLP-1/GIP medications, like tirzepatide (Mounjaro/Zepbound), are primarily given as subcutaneous injections (shots under the skin) using pre-filled pens, typically once weekly, into the abdomen, thigh, or upper arm, though some GLP-1s (like semaglutide oral (Rybelsus)) offer an oral option requiring specific conditions.

Yes, there are key differences: injections deliver the drug directly, offering higher, more consistent absorption (bioavailability) for greater efficacy, while oral drops (like Rybelsus) face stomach acid, requiring larger doses, strict timing (fasting), and often yield less weight loss than injections, though they avoid needles and show promise with newer dual-GIP/GLP-1 drugs like tirzepatide. 

GLP-1/GIP medications promote weight loss by mimicking natural hormones to signal the brain to reduce appetite and increase feelings of fullness (satiety), while also slowing stomach emptying, leading to less food intake, reduced cravings, and better blood sugar control, ultimately helping you eat less and feel satisfied longer.